( STANFORD Calif.--(BUSINESS WIRE)--May ...)Limiting Eligibility for Medical Studies Can Omit Women,,African-Americans, Stanford Study Finds,Health

STANFORD, Calif.--(BUSINESS WIRE)--May 24, 2007 - A new analysis has found that many alcohol treatment studies are designed in ways that inadvertently omit women and African-Americans from participation. The Stanford University School of Medicine researcher who led the effort said the findings should remind all scientists that strict study eligibility criteria can have unintended, negative consequences.

In reviewing data from a pool of 100,000 alcohol treatment patients, Keith Humphreys, PhD, professor of psychiatry and behavioral sciences, determined that women and African-Americans were substantially more likely to be excluded from treatment studies than men or non-African-American patients, because of eligibility requirements involving psychiatric problems, employment and housing problems, and drug use.

"Researchers' own study designs are thwarting their good-faith efforts to recruit representative patient samples," said Humphreys, whose paper will be published in the June issue of Alcoholism: Clinical and Experimental Research. "If we want health-care practice to be guided by research, we're going to have to do a better job at studying patients that clinicians actually see."

Medical studies typically exclude certain patients from participation. While some exclusions are often necessary--to protect patient safety, for example--Humphreys suspects researchers often use exclusions in their studies out of habit or tradition. In other cases, researchers may use eligibility criteria to enroll only "desirable" patients in their study, in an effort to make the trial run smoothly or to increase the chances that a favored treatment will show positive outcomes.

Humphreys said such exclusions could have dangerous implications. "If treatments are tested on, and developed for, only part of the population, that means everyone excluded is at greater risk when they use health care," said Humphreys. For t
'"/>

Page: 1 2 3
Related medicine technology :

1. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
2. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
5. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
6. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
7. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
8. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
9. World First Medical Treatment Announced by Researchers at Queen Mary University London and University of Leicester
10. Introgen and Clinical Collaborators to Report New Results with Advanced-Stage Cancer Therapies at Upcoming Medical Meetings
11. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings